Difference between revisions of "Mitoxantrone (Novantrone)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[B-cell acute lymphoblastic leukemia]] |
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| Line 17: | Line 17: | ||
*[[Marginal zone lymphoma]] | *[[Marginal zone lymphoma]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| + | *[[T-cell acute lymphoblastic leukemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 33: | Line 34: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
| Line 50: | Line 50: | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | [[Category:T-cell acute lymphoblastic leukemia medications]] | ||
[[Category:FDA approved in 1987]] | [[Category:FDA approved in 1987]] | ||
Revision as of 01:58, 24 August 2018
General information
Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Chronic lymphocytic leukemia (CLL/SLL)
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Prostate cancer
- T-cell acute lymphoblastic leukemia
Patient drug information
- Mitoxantrone (Novantrone) patient drug information (Chemocare)[3]
- Mitoxantrone (Novantrone) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/23/1987: Initial FDA approval for the initial treatment of acute nonlymphocytic leukemia (ANLL)
- 11/13/1996: Approved in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.
Also known as
- Brand names: Nitrol, Novantron, Novantrone
References
- Drugs
- Intravenous medications
- Irritant chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- B-cell acute lymphoblastic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Hodgkin lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Prostate cancer medications
- T-cell acute lymphoblastic leukemia medications
- FDA approved in 1987